well now we can say the gap up in the chart got filled in. Didn't think it would happen but hopefully now we get on with news on the blockbuster drugs in development and management learned how not to do a stock offering!
when pressed as to why Achillion chose to make this offering at a 20% discount, the IR rep remarked "we had an urgent need to fill a gap in our coffers and a gap in the chart without which we can't reach the phase x goal of $12 suggested by our Rotten capital partners. The only gap left to fill now is the gap in investor confidence. That -we don't really care about as investors in our stock are suckers to begin with and can easily fill it with the vacuum in their heads."